Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02587650
Title Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of California, San Francisco
Indications

melanoma

Therapies

Ceritinib

Capmatinib

Regorafenib

Entrectinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST